Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 513-520

  Van Der Linden, Jan W M ^a   Camps, Simone M T ^a   Kampinga, Greetje A ^b   Arends, Jan P A ^b   Debets Ossenkopp, Yvette J ^c   Haas, Pieter J A ^d   Rijnders, Bart J A ^e   Kuijper, Ed J ^f   Van Tiel, Frank H ^g   Varga, János ^h   Karawajczyk, Anna ⁱ   Zoll, J ^a   Melchers, Willem J G ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF SZEGED   (Hungary)

ⁱ Lead Pharma Medicine BV   (Netherlands)

Author keywords

Aspergillus fumigatus; Azole resistance; Invasive aspergillosis; Prevalence; Voriconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADULT; AGAR DILUTION; AGED; AIR SAMPLING; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; DISEASE SURVEILLANCE; DRUG TREATMENT FAILURE; FEMALE; FUNGUS ISOLATION; GENE SEQUENCE; GENETIC DISTANCE; GENOTYPE; HUMAN; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NETHERLANDS; PATIENT INFORMATION; PERSISTENT INFECTION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; QUESTIONNAIRE; SCHOOL CHILD; SEQUENCE ANALYSIS; SPUTUM ANALYSIS; UNIVERSITY HOSPITAL; WILD TYPE;

ASPERGILLUS FUMIGATUS; AZOLE RESISTANCE; INVASIVE ASPERGILLOSIS; PREVALENCE; VORICONAZOLE;

AGED; AIR MICROBIOLOGY; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CHILD; DRUG RESISTANCE, FUNGAL; FEMALE; GENES, FUNGAL; GENOTYPE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; MYCOLOGICAL TYPING TECHNIQUES; NETHERLANDS; PYRIMIDINES; QUESTIONNAIRES; RESIDENCE CHARACTERISTICS; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; TRIAZOLES; YOUNG ADULT;

EID: 84880934076     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit320     Document Type: Article

References (36)

1. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327-360.
2. Pfaller M, Boyken L, Hollis R, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 2011; 49:586-90.
3. Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole crossresistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568-72.
4. Verweij PE, Te Dorsthorst DT, Rijs AJ, et al. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40:2648-50.
5. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123-9.
6. Snelders E, van der Lee HAL, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5:e219.
7. Van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis 2011; 17:1846-54.
8. Van der Linden JWM, Jansen RR, Bresters D, et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 48:1111-3.
9. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007; 356:1481-3.
10. Snelders E, Huis In't Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009; 75:4053-7.
11. Snelders E, Camps SM, Karawajczyk A, et al. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One 2012; 7:e31801.
12. Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009; 9:789-95.
13. Van der Linden JWM, Arendrup MC, Verweij PE, et al. Prospective international surveillance of azole resistance in Aspergillus fumigatus: SCARE-Network. Abstract M-490. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2011.
14. Howard SJ, Cesar D, Anderson MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15:1068-76.
15. Mellado E, Garcia-Effron G, Alcázar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51:1897-904.
16. Lagrou K, De Vleeschouwer J, Meerseman W, et al. Triazole resistance among 229 clinical Aspergillus fumigatus isolates. Abstract 33. In: 3rd Advances Against Aspergillosis. Miami, Florida, 2008.
17. Mortensen KL, Johansen HK, Fuursted K, et al. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis 2011; 30:1355-63.
18. Chryssanthou E. In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B acquired resistance to itraconazole. Scand J Infect Dis 1997; 29:509-12.
19. Alanio A, Sitterlé E, Liance M, et al. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J Antimicrob Chemother 2011; 66:371-4.
20. Chowdhary A, Kathuria S, Randhawa HS, et al. Isolation of multipletriazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012; 67:362-6.
21. Lockhart SR, Frade JP, Etienne KA, et al. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011; 55:4465-8.
22. Rath PM, Buchheidt D, Spiess B, et al. First reported case of azoleresistant Aspergillus fumigatus due to the TR/L98H mutation in Germany. Antimicrob Agents Chemother 2012; 56:6060-1.
23. Hamprecht A, Buchheidt D, Vehreschild JJ, et al. Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. Euro Surveill 2012; 17:20262.
24. Camps SMT, Rijs AJMM, Klaassen CHW, et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol 2012; 50:2674-80.
25. Van der Linden JWM, Arendrup MC, van der Lee HAL, et al. Azole containing agar plates as a screening tool for azole resistance of Aspergillus fumigatus. Mycoses 2009; 52:S1-19.
26. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2008.
27. Camps SMT, van der Linden JWM, Li Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 2012; 56:10-6.
28. Samson RA, Hong SB, Peterson SW, et al. Polyphasic taxonomy of Aspergillus section Fumigati and its teleomorph, Neosartorya. Stud Mycol 2007; 59:147-203.
29. Park SDE. Trypanotolerance in West African cattle and the population genetic effects of selection. PhD dissertation, University of Dublin, 2001.
30. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the EORTC/MSG. Clin Infect Dis 2008; 46: 1813-21.
31. Hodiamont CJ, Dolman KM, Ten Berge IJ, et al. Multiple-azoleresistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009; 47:217-20.
32. Snelders E, Karawajczyk A, Verhoeven RJ, et al. The structure-function relationship of the Aspergillus fumigatus cyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance. Fungal Genet Biol 2011; 48:1062-70.
33. Vermeulen E, Maertens J, Schoemans H, Lagrou K. Azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation emerging in Belgium. Euro Surveill 2012; 29:17.
34. Seyedmousavi S, Brüggemann RJ, Melchers WJ, Rijs AJ, Verweij PE, Mouton JW. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis. J Antimicrob Chemother 2013; 68:385-93.
35. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE. In vitro interaction of voriconazole combined with anidulafungin against triazole resistant Aspergillus fumigatus. Antimicrob Agents Chemother 2013; 57:796-803.
36. Seyedmousavi S, Melchers WJG, Mouton JW, Verweij PE. Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 2013; 57:1866-71.